In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer
F1000Research · 11.01.2024 · 11 · 516
DOI: 10.12688/f1000research.110072.4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift F1000Research, online erschienen am 11.01.2024. Verfasst von Mohammed J Al-Zobaidy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Androgen Receptor Antagonists, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The author(s) declared that no grants were involved in supporting this work..
Abstract (Originalsprache)
Background
Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases. Despite advances in treatment against prostate cancer, it can become resistant to drugs. Therefore, the aim of current study was to search and identify binding sites for the repositioning of drugs by computational methods (docking).
Methods
Based on the protein structure of the wild androgen receptor, the analysis parameters (22x22x22 on the X, Y, and Z axes) were established.
Results
The interactions of the natural ligands with androgen receptor were 10.0 (testosterone) and 10.8 (dihydrotestosterone) while mutated androgen receptor (T877A) had a low affinity with testosterone and dihydrotestosterone (-5.3 and -6.7, respectively). In the interactions of both receptors with the reported inhibitors (antagonists), a decrease with Bicalutamide (-8.3 and -4.3, respectively) and an increase in affinity with Flutamide and Nilutamide (-7.7 and 8.6, wild AR; -8.7 and -9.3 AR T877A) were observed. As for Enzalutamide and Apalutamide (second-generation antagonists), the change was minimal between wild androgen receptor and T877A (-7.6 and -7.7; -7.3 and -7.3, respectively). The change in the affinity of the ligands with androgen receptor and androgen receptor T877A shows how a mutation alters the bonds between these molecules.
Conclusion
The identification of key sites and potent inhibitors against abnormal androgen receptor functions will enrich prostate cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.
- Department of Pharmacy, Bilad Alrafidain University College, Diyala Junction, Baqubah, Diyala, Iraq.
- Dr Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq.
Förderung
- The author(s) declared that no grants were involved in supporting this work.
Zitieren
APA
Al-Zobaidy, M. J., Akeel Al-Hussaniy, H., & S Al-Tameemi, Z. (2024). In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer. F1000Research, 11, 516. https://doi.org/10.12688/f1000research.110072.4
Vancouver
Al-Zobaidy MJ, Akeel Al-Hussaniy H, S Al-Tameemi Z. In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer. F1000Research. 2024;11:516. doi:10.12688/f1000research.110072.4
BibTeX
@article{AlZobaidy2024,
author = {Al-Zobaidy, Mohammed J and Akeel Al-Hussaniy, Hany and S Al-Tameemi, Zahraa},
title = {In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer},
journal = {F1000Research},
year = {2024},
volume = {11},
pages = {516},
doi = {10.12688/f1000research.110072.4}
}
EUVIMED